Drugs / AGTC-402
AGTC-402
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02935517 | Aug 2017 → Aug 2022 overdue | achromatopsia | Beacon Therapeutics | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AGTC-402 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02935517 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “recombinant adeno-associated virus vector” NCT02935517 ↗ |
| Route | Other | “administered to one eye by subretinal injection” NCT02935517 ↗ |
| Target | CNGA3 | “expresses the CNGA3 gene” NCT02935517 ↗ |